Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/4285
| Predicate | Object |
|---|---|
| rdf:type | |
| rdfs:label |
Methenamine Hippurate (Tablet)
|
| dailymed-instance:dosage |
1 tablet (1.0 g) twice daily (morning and night) for adults and pediatric patients over 12 years of age. 1/2 to 1 tablet (0.5 to 1.0 g) twice daily (morning and night) for pediatric patients 6 to 12 years of age. Since the antibacterial activity of methenamine hippurate tablets USP is greater in acid urine, restriction of alkalinizing foods and medications is desirable. If necessary, as indicated by urinary pH and clinical response, supplemental acidification of the urine should be instituted. The efficacy of therapy should be monitored by repeated urine cultures.
|
| dailymed-instance:descripti... |
Methenamine hippurate tablets USP are available as 1 g oval shaped, scored and peach colored tablets. Chemically, methenamine hippurate is Hexamethylene-tetramine monohippurate. The molecular formula of methenamine hippurate is CHNOand molecular weight is 319.36. Its structural formula is: Each methenamine hippurate tablet USP intended for oral administration contains 1 g of methenamine hippurate. In addition, it also contains the following inactive ingredients: colloidal silicon dioxide, magnesium stearate, povidone K29/32, saccharin sodium and FD&C Yellow #6 Aluminum Lake as a color additive.
|
| dailymed-instance:clinicalP... |
Microbiology:
Methenamine hippurate USP has antibacterial activity because the methenamine component is hydrolyzed to formaldehyde in acid urine. Hippuric acid, the other component, has some antibacterial activity and also acts to keep the urine acid. The drug is generally active against E. coli
, enterococci and staphylococci. Enterobacter aerogenes
is generally resistant. The urine must be kept sufficiently acid for urea-splitting organisms such asProteus
and Pseudomonas
to be inhibited. Human Pharmacology:
Within 1/2 hour after ingestion of a single 1-gram dose of methenamine hippurate USP, antibacterial activity is demonstrable in the urine. Urine has continuous antibacterial activity when methenamine hippurate USP is administered at the recommended dosage schedule of 1 gram twicedaily. Over 90% of methenamine moiety is excreted in the urine within 24 hours after administration of a single 1-gram dose. Similarly, the hippurate moiety is rapidly absorbed and excreted, and it reaches the urine by both tubular secretion and glomerular filtration. This action may be important in older patients or in those with some degree of renal impairment.
|
| dailymed-instance:activeIng... | |
| dailymed-instance:contraind... |
Methenamine hippurate tablets USP are contraindicated in patients with renal insufficiency, severe hepatic insufficiency, or severe dehydration. Methenamine preparations should not be given to patients taking sulfonamides because some sulfonamides may form an insoluble precipitate with formaldehyde in the urine.
|
| dailymed-instance:supply |
Methenamine hippurate tablets USP 1 g are supplied as peach, oval shaped compressed tablets debossed���cor���on the left and���139���on the right side of bisect on one side and other side is plain. They are supplied as follows: Bottles of 100 (NDC 64980-119-01)
|
| dailymed-instance:activeMoi... | |
| dailymed-instance:inactiveI... | |
| dailymed-instance:precautio... |
Prescribing methenamine hippurate tablets USP in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.<br/>Information for Patients: Patients should be counseled that antibacterial drugs including methenamine hippurate tablets USP should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When methenamine hippurate tablets USP are prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by methenamine hippurate tablets USP or otherantibacterial drugs in the future.
|
| dailymed-instance:genericMe... |
methenamine hippurate
|
| dailymed-instance:fullName |
Methenamine Hippurate (Tablet)
|
| dailymed-instance:adverseRe... |
Minor adverse reactions have been reported in less than 3.5% of patients treated. These reactions have included nausea, upset stomach, dysuria, and rash.
|
| dailymed-instance:warning |
Large doses of methenamine (8 grams daily for 3 to 4 weeks) have caused bladder irritation, painful and frequent micturition, albuminuria, and gross hematuria.
|
| dailymed-instance:indicatio... |
Methenamine hippurate tablets USP are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. This drug should only be used after eradication of the infection by other appropriate antimicrobial agents. To reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine hippurate tablets USP and other antibacterial drugs, methenamine hippurate tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
|
| dailymed-instance:represent... | |
| dailymed-instance:routeOfAd... | |
| dailymed-instance:name |
Methenamine Hippurate
|